Evidence map›Paper›PMID 40810802›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Christian Bayerl, Jonas Kaufmann, Giulia Metzger, Julian M M Rogasch, Holger Amthauer, Imke Schatka, Winfried Brenner, Markus van der Giet, Christian Furth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christian BayerlDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. christian.bayerl@charite.de.ORCID 0000-0001-7107-3934
Jonas KaufmannDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Giulia MetzgerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Julian M M RogaschDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Holger AmthauerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Imke SchatkaDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Winfried BrennerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Markus van der GietDepartment of Nephrology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Christian FurthDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRetroperitoneal fibrosis (RPF) is a rare inflammatory disease, that, if left untreated, can lead to ureteral obstruction and subsequent renal impairment. First-line treatment is prednisolone, with rituximab, often used for refractory cases. This study evaluates treatment response in both [

methods50 patients with RPF underwent at least two [

resultsAll PET parameters showed significant correlations with CT

conclusionOur findings underscore the superiority of PET against CT in therapy monitoring of RPF, especially in the detection of progression at FU2. Higher BL MAV correlated with progression at FU2, indicating its potential as a predictive marker. Still, especially when PET is not available, CT can be considered for initial therapy monitoring.

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRetroperitoneal FibrosisAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedPrednisoloneRadiopharmaceuticalsRituximabTreatment OutcomeFluorodeoxyglucose F18PrednisoloneRadiopharmaceuticalsRituximabMetabolic active volumePrednisoloneRetroperitoneal fibrosisRituximab

Identifiers

PMID40810802
PMCPMC12830415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.